Federal Aviation Administration

DOT/FAA/AM-10/10
Office of Aerospace Medicine
Washington, DC 20591

Toxicological Findings in 889 Fatally Injured Obese Pilots Involved in Aviation Accidents

Sabra R. Botch
Marc S. Davidson
Eduard M. Ricaurte
Arvind K. Chaturvedi
Civil Aerospace Medical Institute
Federal Aviation Administration
Oklahoma City, OK 73125

May 2010

Final Report

OK-10-0077-JAH

NOTICE

Technical Report Documentation Page

1. Report No.	2. Government Accession No.	3. Recipient's Catalog No.
DOT/FAA/AM-10/10		

4. Title and Subtitle	5. Report Date
Toxicological Findings in 889 Fatally Injured Obese Pilots Involved in Aviation Accidents	May 2010
	6. Performing Organization Code
7. Author(s)	8. Performing Organization Report No.
Botch SR, Davidson MS, Ricaurte EM, Chaturvedi AK	
9. Performing Organization Name and Address	10. Work Unit No. (TRAIS)
FAA Civil Aerospace Medical Institute P.O. Box 25082 Oklahoma City, OK 73125	11. Contract or Grant No.
12. Sponsoring Agency name and Address	13. Type of Report and Period Covered
Office of Aerospace Medicine Federal Aviation Administration 800 Independence Ave., S.W. Washington, DC 20591	14. Sponsoring Agency Code

15. Supplemental Notes

Work was accomplished under approved task AM-B-10-TOX-202.

16. Abstract

Obesity continues to be a public health concern and its impact on aviation community has not been fully evaluated. Toxicological findings in fatally injured aviation accident obese pilots were examined. The Civil Aerospace Medical Institute's (CAMI's) Scientific Information System was used to develop a dataset, entailing fatally injured obese pilots involved in aviation accidents, 1990–2005. A pilot with a body mass index (BMI) of $\geq$ 30 $kg \cdot m^{\bullet 2}$ was considered obese. Toxicological results and aeromedical histories of these aviators were retrieved from the CAMI toxicology and medical certification databases, and the cause/factors in the related accidents were retrieved from the National Transportation Safety Board's aviation accident database. In 311 of the 889 pilots, carbon monoxide, cyanide, ethanol, and drugs were found, and glucose and hemoglobin A_{1c} (HbA_{1c}) were elevated. Many of these drugs were for treating overweight, depression, hypertension, and cardiac conditions. In a pilot (BMI: 39.33 $kg \cdot m^{\bullet 2}$) wherein phentermine was detected, vitreous and urinary glucose concentrations were 301 and 6,050 mg 11.5 $dL^{\bullet 1}$, respectively; HbA_{1c} was 12.4%. Of the 889 pilots, 107 had an obesity-related medical history. The health and/or medical condition(s) of, and/or the use of ethanol and/or drugs by, pilots were the cause/factors in 55 (18%) of the 311 accidents. Although the drugs found are commonly used in the general population, they were primarily used for treating obesity-related medical conditions. Findings emphasize monitoring of obesity and diabetes in pilots and understanding the potential implications of these health conditions in relation to flight safety.

17. Key Words	18. Distribution Statement
Forensic Science, Toxicology, Obesity, Pilot Fatalities, Drugs, Ethanol, Glucose, Hemoglbin A_{1c}, Civil Aviation Accident Investigation	Document is available to the public through the Defense Technical Information Center, Ft. Belvoir, VA 22060; and the National Technical Information Service, Springfield, VA 22161

19. Security Classif. (of this report)	20. Security Classif. (of this page)	21. No. of Pages	22. Price
Unclassified	Unclassified	15	

Form DOT F 1700.7 (8-72) Reproduction of completed page authorized

CONTENTS

Toxicological Findings in 889 Fatally Injured Obese Pilots Involved in Aviation Accidents

INTRODUCTION

Obesity in the United States general population has been on the rise over the past 25 years and continues to be a public health concern (20). In 2007, the prevalence rates for diabetes and obesity in the United States were $\geq$ 10.6% and $\geq$ 30.9%, respectively (9); the dominance for diabetes in U.S. counties ranged from 3.7% to 15.3% (median: 8.4%) and for obesity from 12.4% to 43.7% (median: 28.4%). Individuals with a body mass index (BMI) $\geq 30\ kg \cdot m^{-2}$ are considered obese (9, 26), and BMI is a generally accepted practical approach for assessing fat (21). However, this index has limitations—for example, overestimation of body fat in very muscular persons and underestimation in elderly (4). In spite of these limitations, BMI is an accepted method for measuring body fat based on height and weight, regardless of age, gender, race, or ethnicity (18, 19, 26). Individuals with obesity have patho-physiological potentials to develop a number of medical conditions that could be associated with the adverse effects of excess visceral abdominal fat (4, 5, 34). Abdominal obesity has been linked with coronary heart disease (22). The comorbidities of obesity include diabetes, high cholesterol, hypertension, cardiovascular disease, depression, obstructive sleep apnea, stroke, arthritis, certain cancers, and risk of disabilities and all-cause mortality (2, 4, 5, 27, 34).

Because of the growing concern with the medical issues related to obesity, it is important to understand and address this issue in the aviation community, particularly with respect to the airman seeking or maintaining the required medical certificate to fly an aircraft. In a 10-year study, it has been found that commercial pilots who were obese had a 22% higher risk of cardiovascular disease than their counterparts with normal BMI values (29). In the 2008 Aerospace Medical Association panel on diabetes, it was reported that the median BMI in the U.S. civilian pilot population was increasing (30, 35). Therefore, it is important that the aviation medical community monitor obesity and its potential implications with respect to flight safety.

The Federal Aviation Administration's (FAA's) Civil Aerospace Medical Institute (CAMI; Oklahoma City, OK) has been determining concentrations of glucose in vitreous fluid and urine and of hemoglobin A_{1c} (HbA_{1c}) in blood samples collected from pilots who were fatally injured in civil aviation accidents. This determination is carried out to establish if the disease of diabetic pilots was controlled at the time of the accident and/or to identify pilots with undiagnosed or unreported diabetes (7, 11, 37). Findings of these studies concluded that all of the aviators were not aware of, or did not report, elevated glucose levels or the diabetic condition. Concentrations of glucose and HbA_{1c} from fatally injured aircraft accident victims have been helpful in establishing whether the hyperglycemia-related performance impairment was the probable cause or a contributory factor in the accidents. Aeromedical aspects of obesity and diabetes have been elaborated in the literature (30, 35, 36), but toxicological findings in obese pilots have not been examined. The present study was conducted to evaluate and discuss such findings in the fatally injured obese aviators. Also, examined in the study were the pre-existing medical conditions mentioned in the medical certifications of those pilots and the probable cause/contributing factors in those aviation accidents, as concluded by the National Transportation Safety Board (NTSB) (25).

MATERIALS AND METHODS

Scientific Information System (SIS) Database

The SIS aviation safety database of the U.S. pilot population from 1983 through 2005 was developed at CAMI (28, 30, 31). For the present study, this database was used to obtain a population dataset of pilots spanning the period of 16 years (1990–2005). Obtained by performing a longitudinal analysis of the entire airman population residing in the SIS database, the dataset utilized in the present study was associated with those aviators who were obese and involved in civil aviation accidents. This dataset consisted of fatally, as well as non-fatally, injured aviators.

Toxicology Database

Since 1990, a toxicology database for civil aircraft accident fatalities has been maintained at CAMI (15). In this database, toxicological results, including applicable glucose and HbA_{1c} concentrations and DNA profiling, are electronically stored (14, 15). Also, incorporated in the database are other relevant data concerning the accidents and the victims (10, 15). Such information is obtained from the FAA Administrator's Daily Alert Bulletin, the NTSB Web site, the FAA airman and medical certification records, and other sources. The CAMI toxicology

database was searched for the 16-year period (1990–2005) for the fatally injured pilots of the obese pilot population dataset (see the previous subsection, Scientific Information System [SIS] database) from whom postmortem samples were submitted to CAMI.

Medical Certification Database

The CAMI medical certification database (Document Information Workflow System) was used to retrieve necessary information from the most recent medical examination pertaining to a particular aviator who was fatally injured in an aviation accident that occurred during 1990–2005. The information consisted of examination date, height, weight, medications used, medical conditions and associated pathology codes, and medical certificate type. Obesity (BMI $\geq$ 30 kg·m^{-2}) was re-calculated by height (m) and weight (kg) recorded in the medical examination of the aviator prior to the fatal accident to confirm that the BMI value was consistent with the criterion for determining obesity. The pathology codes documented on the medical examination records were used to identify airmen with medical conditions associated with obesity. Information on the medical certificate types (first-, second-, or third-class) of aviators (17) was also retrieved from the database.

Aviation Accident Database

The NTSB's aviation accident database was used to obtain accident-related information such as flight categories, probable cause, and contributing factors in the accidents (25).

Biological Specimens and Toxicological Analyses

Biological samples collected from pilot fatalities associated with U.S. civil aviation accidents are submitted to CAMI in the FAA TOX-BOX evidence containers for toxicological analyses (3, 14, 15). The sample submission is requested by the NTSB, in coordination with the FAA Office of Accident Investigation (Washington, DC), for the investigation of aircraft accidents occurring within the jurisdiction of the United States. The types of samples generally received at CAMI are blood, urine, vitreous fluid, spinal fluid, brain, lung, heart, liver, kidney, muscle, and other biological samples.

Following the standard operating procedures of CAMI's laboratory, the submitted samples are analyzed for the presence of combustion gases, ethanol/volatiles, and drugs. The presence of these analytes is analytically demonstrated by screening, followed by confirmation and/or quantitation. The combustion gases include carbon monoxide as carboxyhemoglobin (COHb) and hydrogen cyanide as cyanide ion (CN^-); the drugs entail a wide range of prescription, nonprescription, and illegal drugs (13, 15). Vitreous fluid and urine samples are analyzed for glucose; blood for hemoglobin A_{1c} (HbA_{1c}) (7, 11). Glucose and HbA_{1c} analyses were formally implemented on a routine basis in the CAMI laboratory in 1998 and 2001, respectively. Concentrations of glucose > 125 mg·dl^{-1} in vitreous fluid and > 100 mg·dl^{-1} in urine are considered elevated (7, 11). Postmortem blood HbA_{1c} values > 6.0% correlate well with a known history of diabetes and with the elevated vitreous fluid and/or urine glucose levels in the fatally injured pilots and, thus, the HbA_{1c} values > 6.0% are considered elevated (7, 11, 12, 37). DNA profiling is performed on case samples in which there is a doubt about the identity of the submitted samples (14). These toxicological evaluations are summarized in a 2009 review (10).

RESULTS

SIS Dataset

The obtained SIS dataset was associated with those aviators whose BMI values were $\geq$ 30 kg·m^{-2} and who were involved in fatal or non-fatal U.S. civil aviation accidents that occurred from 1990 through 2005. The number of pilots who met these parameters was 3,876. Of this population, 967 pilots were fatally injured; this number was re-confirmed by the NTSB database. Of the 967 fatalities, postmortem samples from 897 (93%) were submitted to CAMI. With eight aviators, there were discrepancies in the SIS and toxicology databases with respect to the data elements (such as age and gender) and the misclassification of a pilot as to be a passenger, and/or the submitted samples of the pilot were not toxicologically analyzed. Therefore, these eight pilots were excluded from the 897 dataset, and the retrieval of medical, toxicological, and accident investigation information from the databases was limited to 889 pilots (Fig. 1).

Based upon the height and weight values recorded at the time of the most recent aviation medical examination, the BMI values of all of the 889 aviators were reconfirmed that the values were equal to or greater than 30 kg·m^{-2} prior to the accidents (Table I). The majority of the aviators in the toxicology dataset were male—that is, 876 (98.5%) males and 13 (1.5%) females.

Medical Certification and History

Of 889 aviators, 108 held first-class, 344 second-class, and 437 third-class medical certificates (17). With respect to flying ratings, 436 pilots held private, 295 commercial, 123 airline transport, and 33 student certificates (17). Two pilots were not certificated.

One hundred seven (12%) of the 889 aviators had a medical history that could be related to obesity. Based on pathological codes that are used to register an aviator's



Figure 1. A flowchart representation of 889 fatally injured obese civil aviation accident pilots whose postmortem biological samples were toxicologically evaluated.

Table I. Mean BMI ($kg \cdot m^{-2}$), Height (m), and Weight (kg) Values of Fatally Injured Obese Male and Female Pilots Involved in Aviation Accidents

Pilots	BMI (SD_n*; Range)	Height (SD_n; Range)	Weight (SD_n; Range)
Males (n = 876)	33.14 (3.14; 30.02–61.62)	1.78 (0.08; 1.30–2.01)	105.45 (12.32; 71.67–175.54)
Females (n = 13)	34.16 (3.93; 30.10–43.57)	1.69 (0.04; 1.60–1.75)	97.87 (13.84; 77.11–127.01)

*Standard deviation (SD_n) based on the entire population given as argument—that is, data taken from every member of the population.

Table II. Medical Conditions Mentioned in Medical Certification Examination Records of Fatally Injured Obese Pilots Involved in Aviation Accidents

Medical Conditions	Pilots
Hypertension controlled by medication	51
Calculus-bladder/renal/ureteral	19
Diabetes controlled by diet and/or disturbance of carbohydrate metabolism	11
Labile hypertension	10
Diabetes controlled by hypoglycemic drugs	6
Glycosuria or sugar in the urine	5
Coronary artery disease/heart disease	5
Coronary artery bypass surgery	3
Unspecified cardiac disorder	3
Hardening arteries, arteriosclerosis other than coronary	2
Coronary angioplasty	2
Myocardial infarction	1
Angiography with 50% or less occlusion	1
Other genitourinary condition	2
Renal disease	1

*More than one medical condition was reported in some records.

medical history, these 107 aviators reported or were diagnosed with the medical conditions shown in Table II. More than one medical condition was reported in the records of some of the 107 pilots. The medical conditions—for example, diabetes, depression, hypertension, and cardiovascular conditions—reported in the records were conditions primarily associated with obesity. No obesity-related medical conditions were mentioned in the medical certification records of the remaining pilots.

Toxicological Findings

Of the 889 fatalities (cases), 578 were determined to be negative; the remaining 311 were positive cases (Fig. 1). In these positive cases, foreign substances—carbon monoxide, hydrogen cyanide, ethanol, and drugs—were found and/or endogenous substances—glucose and HbA_{1c}—were elevated. In some cases, the presence of more than one foreign substance and the elevation of more than one endogenous substance (glucose and HbA_{1c}) were observed. Therefore, those cases were counted more than once. Of the 311 fatalities, 11 were positive for COHb and/or CN^- and 302 for ethanol and/or drugs (Fig. 2). In additional 11 fatalities, glucose and/or HbA_{1c} were elevated; ethanol and/or drugs were also found in seven of these 11 fatalities. Along with concentrations of COHb, CN^-, glucose, and HbA_{1c}, the list of drugs found in the fatalities are tabulated in Tables III–V. Associated with COHb, CN^-, glucose, and HbA_{1c} cases, the cause/factors in aviation accidents and medical histories of pilots are also mentioned in Tables III and V.

As exhibited in Figure 3, ethanol was present in 36 aviators. The Drug Enforcement Administration's (16) controlled substances of Schedules I and II were found in 38 pilots and of Schedules III, IV, and V in two. The controlled substances include drugs such as amphetamine/methamphetamine, cocaine, Δ^9-tetrahydrocannabinol (THC), and benzodiazepines (16). Prescription drugs were present in 203 pilots and non-prescription (over-the-counter) drugs in 303. Considering that more than one substance was present in some of these fatalities, the total number of instances for the presence of substances (ethanol/drugs) was 582. These substances (drugs) ranged from the commonly used prescription drugs—such as narcotic analgesics, benzodiazepines, and cardiovascular medications—to non-prescription drugs—such as antihistaminics, decongestants, non-narcotic analgesics, and quinine (Table IV). Including ethanol, some of these substances can cause performance impairment.



Figure 2. The number of pilot fatalities (cases) in which COHb, CN^-, ethanol, and drugs were found, and glucose and HbA_{1c} were elevated.

Table III. Blood COHb and CN^- Concentrations in 11 Fatally Injured Obese Pilots Involved in Aviation Accidents

Number	COHb (%)	CN^- ($\mu g \cdot ml^{-1}$)	Fire Status	Drugs Found in Biological Samples*	Pilot's Health and/or Medical Conditions as the Cause/Factors in the Accidents as Determined by the NTSB
1	12	0.48	Ground fire	—†	—
2	12	0.71	Ground fire	—	—
3	—	0.50	Ground fire	—	Incapacitation of the pilot in command
4	23	0.34	Ground fire	—	—
5	16	—	—	—	Physical impairment of the pilot‡
6	22	2.22	Ground fire	—	—
7	13	—	Ground fire	—	—
8	33	0.93	Ground fire	Lorazepam	—
9	13	—	Ground fire	—	—
10§	45	—	—	Atenolol Diphenhydramine Pseudoephedrine Triamterene	Failure of the left muffler, resulting in a carbon monoxide leak into the cabin rendering the pilot incapacitated
11§	53	—	Ground fire	—	—

*Where possible, based upon multi-analyses in at least two different sample types.

†No analysis, negative findings, no drugs found, or no cause/factor.

‡Pilot was a mechanic and had been exposed to running engines in a non-ventilated shop the day/evening prior to the accident.

§Hypertension controlled by medication.



Figure 3. Ethanol and drugs found in the fatally injured obese pilots involved in aviation accidents.

Table IV. Drugs and Metabolites Found in the Fatally Injured Obese Pilots Involved in Aviation Accidents

Drugs* and Metabolites				
Controlled Substances				
Amphetamine	Methamphetamine	Cocaine	Δ^9-Tetrahydrocannabinol (THC)/THC Carboxylic Acid	
Prescription Drugs				
Alprazolam	Amitriptyline	Amlodipine	Atenolol	Atropine
Azacyclonol	Bisoprolol	Bupropion	Butalbital	Carbamazepine
Cimetidine	Citalopram	Codeine	Cyclobenzaprine	Desipramine
Diazepam	Diltiazem	Dihydrocodeine	Donepezil	Fenfluramine
Fluoxetine/ Norfluoxetine	Gemfibrozil	Hydrocodone	Hydromorphone	Hydroxyzine
Imipramine	Labetalol	Lorazepam	Meclizine	Metoprolol
Midazolam	Morphine	Nizatidine	Nordiazepam	Nortriptyline
Oxycodone	Oxymorphone	Oxazepam	Pantoprazole	Paroxetine
Pentobarbital	Phenytoin	Phentermine	Propranolol	Propoxyphene/ Norpropoxyphene
Ranitidine	Sertraline/ Desmethyl-sertraline	Sildenafil/ Desmethylsildenafil	Temazepam	Theophylline
Trazodone	Triamterene	Trimethoprim	Verapamil/ Norverapamil	
Nonprescription Drugs				
Acetaminophen	Brompheniramine	Cetirizine	Chlorpheniramine	Dextrorphan
Dextromethorphan	Diphenhydramine	Doxylamine	Ephedrine	Hydrochloro-thiazide
Naproxen	Lansoprazole	Lidocaine	Omeprazole	Pheniramine
Phenyl-propanolamine	Phenyltoloxamine	Pseudoephedrine	Quinine	Salicylate

*Depending upon the formulation and doses of these drugs in a particular pharmaceutical preparation, some of these drugs may fall in more than one category—that is, a drug may fall in the controlled substance, prescription, and/or non-prescription category.

Table V. Toxicological Findings and Medical Histories of 11 Fatally Injured Obese Aviation Accident* Pilots With Elevated Glucose and HbA_{1c} Concentrations

Number	Glucose ($mg \cdot dl^{-1}$)		Blood HbA_{1c} (%)	Drugs Found in Biological Samples†	Medical History
	Vitreous Fluid	Urine			
1	45	189	—‡	Diltiazem	Diabetes controlled by hypoglycemic drugs
2	147	65	—	Nizatidine	—
3	109	—	4.5	—	—
4	125	—	6.3	Diphenhydramine Chlorpheniramine	Diabetes controlled by diet
5	—	1,438	—	—	Diabetes controlled by diet
6	31	333	4.7	Hydrocodone Dihydrocodeine Hydromorphone	—
7§	301	6,050	12.4	Phentermine	Diabetes controlled by insulin and by oral hypoglycemic drugs
8	16	264	5.3	Midazolam	—
9	—	1,750	—	—	Diabetes controlled by diet
10	—	369	5.8	Diltiazem	Diabetes controlled by hypoglycemic drugs
11	—	5,700	—	—	—

*In none of these accidents, pilot's health and/or medical conditions were the cause/factors, as determined by the NTSB.

†Where possible, based upon multi-analyses in at least two different sample types.

‡No analysis, negative findings, no drugs found, or no medical history.

§BMI: 39.33 $kg \cdot m^{-2}$.

Reported Medications

Of the 311 aviators, 208 had not reported taking any medications to their aviation medical examiners (AMEs); 103 reported taking medication(s). The medications aviators reported to their AMEs were those used in treating hypertension and diabetes and in reducing cholesterol and stomach acid levels. At least one drug of these four groups of medications was the most often reported by 78 of the 103 pilots.

Cause or Contributing Factor

The NTSB concluded that physical impairment of pilots, including fatal cardiovascular events, was a cause or factor in 23 of the 311 accidents. Additionally, impairment of pilots caused by the use of ethanol/drugs was determined to be a cause or factor in 32 accidents. Aircraft-assisted suicide was found the cause of four accidents. The remaining accidents in which the aviator was found positive for ethanol/drugs were attributed to adverse weather conditions, mechanical malfunction, and/or pilot error.

DISCUSSION

Biological samples from 93% of the fatally injured obese pilots were submitted to CAMI for toxicological evaluation. This percentage is comparable to that of a previous study (15); accordingly, samples from approximately 80% (73–92%) of the pilot fatalities of aviation accidents that occurred during the period of 1990 to 2000 were submitted to CAMI. In general, the spectrum of drugs found in the obese pilots was similar to those reported earlier with civil aviation accident pilot fatalities wherein selective serotonin reuptake inhibitors (1) and antihistamines (33) were present. A similar drug usage pattern was notable in epidemiological studies conducted for the period of 1989–2003 for fatally injured aviators involved in aviation accidents (6, 8, 13). Findings of the present study were clearly indicative of the obesity comorbidities such as diabetes, depression, hypertension, and cardiovascular conditions, and the findings were consistent with the medical conditions mentioned in the medical certification examination records of the obese pilots. Obviously, many of the medications were taken for the medical conditions associated with obesity. Medical conditions—such as cardiovascular disease, depression, diabetes, and hypertension—have been linked to obesity (4, 5, 24, 34).

Drugs, including appetite suppressants and antidepressants (23, 38) used for reducing body weight, were found in the pilots, as well. For example, phentermine and fenfluramine were detected in four aviators, phentermine in three, and bupropion in two, though fenfluramine has now been withdrawn from the drug markets due to its side effects, heart valve conditions, pulmonary hypertensions, and cardiac fibrosis (32). Other antidepressants—citalopram, fluoxetine, paroxetine, and sertraline—were also found in the obese pilots. Since pilots are a subset of the general population, the obesity-related medications taken by the aviators could obviously be the case with any group of obese people.

The presence of anticonvulsants, atropine, lidocaine, and narcotic analgesics in the aviators could be associated with the administration of these drugs by emergency health care providers at accident scenes or at hospitals for pain management, resuscitation, seizure control, and/or surgical procedures. Whereas other substances—ethanol, amphetamine/methamphetamine, antidepressants, cardiovascular agents, cocaine, sympathomimetics, and THC—were taken by the pilots prior to the accidents. Many of these substances influence the central nervous system and can impair performance, including motor skills.

Obesity may cause diabetes (34). This does not necessarily mean that an obese person is diabetic or that the diabetes of an individual may not be controlled by diet, exercise, and medications. The current findings suggested that the number of pilots with elevated concentrations of vitreous and/or urine glucose and/or HbA_{1c} is low—that is, 11 (1.2%)—which is supportive of a previous study wherein also low numbers (3.2% of 1,335) of fatally injured pilots of civil aviation accidents (1998–2005) were reported to have elevated vitreous/urine glucose and/or HbA_{1c} levels (11). The drugs found in these 11 obese pilots were a heart medication, a benzodiazepine, antihistaminics, and narcotic analgesics. A weight-reducing drug was found in one case wherein glucose and HbA_{1c} levels were considerably elevated.

It is true that obesity in the general population is increasing with diabetes and continues to be a public health concern (9, 20, 26), and this aspect is also true with pilot population (30, 35). The obesity associated obstructive sleep apnea may lead to daytime sleepiness, which in turn may adversely affect neurological functions (27). One of the other comorbidities of obesity is depression (2, 4, 5, 27, 34). These abnormalities, including sleepiness, may lead to performance impairment. An obese individual may have difficulty in effectively manipulating the controls, particularly in the confined space of a flight deck. The NTSB determined that health/medical conditions and the use of ethanol/drugs were the cause/factors in 55 (18%) of the 311 accidents; aircraft-assisted suicide was the cause of four accidents. The growing concern with the medical issues related to obesity emphasizes the importance of addressing, understanding, and potentially resolving this aeromedical issue. This could be effectively achieved by implementing obesity-related educational programs for aviators and aviation medical examiners. The monitoring

of obesity and diabetes by the aviation medical community and the understanding of potential implications of these medical conditions with respect to flight safety are also crucial. In the aviation community, the obesity-linked abnormal neurological and cognitive functions represent a potential safety concern.

REFERENCES

1. Akin A, Chaturvedi AK. Selective serotonin reuptake inhibitors in pilot fatalities of civil aviation accidents, 1990-2001. Aviat Space Environ Med 2003; 74(11):1169–76.

2. American Obesity Association. Costs of obesity; Retrieved 18 March 2010 from http://obesity1.tempdomainname.com/treatment/cost.shtml.

3. Aviation Safety Act. Aviation Safety Research Act of 1988: Public Law 100-591 [H.R. 4686]. 100th U.S. Cong., 2nd Sess., 102 Stat. 3011 (03 November 1988).

4. Bassuk SS, Manson JE. Overview of the obesity epidemic and its relationship to cardiovascular disease. In: Robinson MK, Thomas A, eds. Obesity and Cardiovascular Disease. New York: Taylor & Francis; 2006:1–32.

5. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89(6):2583–9.

6. Canfield D, Flemig J, Hordinsky J, Birky M. Drugs and alcohol found in fatal civil aviation accidents between 1989 and 1993. Washington, DC: U.S. Department of Transportation, Federal Aviation Administration, Office of Aviation Medicine; 1995 Nov. Report No. DOT/FAA/AM-95/28.

7. Canfield DV, Chaturvedi AK, Boren HK, Véronneau SJ, White VL. Abnormal glucose levels found in transportation accidents. Aviat Space Environ Med 2001; 72(9):813–5.

8. Canfield DV, Hordinsky J, Millett DP, Endecott B, Smith D. Prevalence of drugs and alcohol in fatal civil aviation accidents between 1994 and 1998. Aviat Space Environ Med 2001; 72(2):120–4.

9. Centers for Disease Control and Prevention (CDC). Estimated county-level prevalence of diabetes and obesity --- United States, 2007. Atlanta, GA: CDC Morbidity and Mortality Weekly Report (MMWR), November 20, 2009 / 58(45);1259–63; Retrieved 23 November 2009 from www.cdc.gov/mmwr/preview//mm5845a2.htmmmwr

10. Chaturvedi AK. Aerospace toxicology: an overview. Washington, DC: U.S. Department of Transportation, Federal Aviation Administration, Office of Aerospace Medicine; 2009 Apr. Report No. DOT/FAA/AM-09/8.

11. Chaturvedi AK, Botch SR, Canfield DV, Forster EM. Vitreous fluid and/or urine glucose concentrations in 1335 civil aviation accident pilot fatalities. J Forensic Sci 2009; 54(3):715–20.

12. Chaturvedi AK, Botch SR, Craft KJ. Toxicological findings in 34 fatally injured obese diabetic pilots involved in aviation accidents [abstract]. Aviat Space Environ Med 2009; 80(3):212.

13. Chaturvedi AK, Craft KJ, Canfield DV, Whinnery JE. Toxicological findings from 1587 civil aviation accident pilot fatalities, 1999-2003. Aviat Space Environ Med 2005; 76(12):1145–50.

14. Chaturvedi AK, Craft KJ, Kupfer DM, Burian D, Canfield DV. Application of DNA profiling in resolving aviation forensic toxicology issues. Washington, DC: U.S. Department of Transportation, Federal Aviation Administration, Office of Aerospace Medicine; 2009 Oct. Report No. DOT/FAA/AM-09/19.

15. Chaturvedi AK, Smith DR, Soper JW, Canfield DV, Whinnery JE. Characteristics and toxicological processing of postmortem pilot specimens from fatal civil aviation accidents. Aviat Space Environ Med 2003; 74(3):252–9.

16. Code of Federal Regulations. Title 21—Food and drugs, Chapter II—Drug Enforcement Administration, Department of Justice, Part 1308—Schedules of controlled substances. Washington, DC: U.S. Government Printing Office, 2002.

17. Code of Federal Regulations. Title 14—Aeronautics and space, Chapter I (1-1-06 Edition)—Federal Aviation Administration, Department of Transportation, Subchapter D—Airmen, Parts 60–67. Washington, DC: U.S. Government Printing Office, 2006.

18. D'Mello TA, Yamane GK. Proportion of U.S. civilian population ineligible for U.S. Air Force enlistment based on current and previous weight standards. Brooks City-Base, TX: U.S. Air Force Institute for Operational Health, Risk Analysis Directorate, Risk Assessment Division; 2007 Sep. Report No. IOH-RS-BR-TR-2007-0003.

19. eMedTV and Clinaero Inc. Obesity chart; Retrieved 11 November 2009 from http://weight-loss.emedtv.com/obesity/obesity-chart.html.

20. Gearhardt AN, Corbin WR, Brownell KD. Food addiction: an examination of the diagnostic criteria for dependence. J Addict Med 2009; 3(1):1–7.

21. Heymsfield SB, Allison DB, Heshka S, Pierson RN, Jr. Assessment of human body composition. In: Allison DB, ed. Handbook of Assessment Methods for Eating Behaviors and Weight Related Problems: Measures, Theory, and Research. Thousand Oaks, CA: Sage Publications; 1995:515–60.

22. Jain T, Plutzky J, McGuire DK. Obesity and atherosclerotic vascular disease. In: Robinson MK, Thomas A, eds. Obesity and Cardiovascular Disease. New York: Taylor & Francis; 2006:381–402.

23. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142(7):532–46.

24. Moreira RO, Marca KF, Appolinario JC, Coutinho WF. Increased waist circumference is associated with an increased prevalence of mood disorders and depressive symptoms in obese women. Eat Weight Disord 2007; 12(1):35–40.

25. National Transportation Safety Board (NTSB). The NTSB aviation accident database. 1962. www.ntsb.gov/ntsb/query.asp.

26. NHLBI. The practical guide identification, evaluation, and treatment of overweight and obesity in adults. Washington, DC: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), North American Association for the Study of Obesity; 2000 Oct. Report No. 00-4084.

27. Patel S, Fogel R. Obstructive sleep apnea. In: Robinson MK, Thomas A, eds. Obesity and Cardiovascular Disease. New York: Taylor & Francis; 2006:143–76.

28. Peterman CL, Rogers PB, Véronneau SJH, Whinnery JE. Development of an aeromedical scientific information system for aviation safety. Washington, DC: U.S. Department of Transportation, Federal Aviation Administration, Office of Aerospace Medicine; 2008 Jan. Report No. DOT/FAA/AM-08/1.

29. Qiang Y, Li G, Rebok GW, Baker SP. Body mass index and cardiovascular disease in a birth cohort of commuter air carrier and air taxi pilots. Ann Epidemiol 2005; 15(4):247–52.

30. Rogers PB, Véronneau SJ, Peterman CL. Diabetic pilot epidemiology: 1983 to 2005 [abstract]. Aviat Space Environ Med 2008; 79(3):324.

31. Rogers PB, Véronneau SJH, Peterman CL, Whinnery JE, Forster EM. An analysis of the U.S. pilot population from 1983-2005: evaluating the effects of regulatory change. Washington, DC: U.S. Department of Transportation, Federal Aviation Administration, Office of Aerospace Medicine; 2009 May. Report No. DOT/FAA/AM-09/9.

32. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 2002; 144(6):1065–73.

33. Sen A, Akin A, Craft KJ, Canfield DV, Chaturvedi AK. First-generation H_1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. Aviat Space Environ Med 2007; 78(5):514–22.

34. Steinkraus LW, Cayce W, Golding A. Diabetes mellitus type 2 in aviators: a preventable disease. Aviat Space Environ Med 2003; 74(10):1091–100.

35. Whinnery JE, Forster EM. Diabetes in aviation: an introduction [abstract]. Aviat Space Environ Med 2008; 79(3):323–4.

36. Whinnery JE, Forster EM. Obesity in aviation: an introduction [abstract]. Aviat Space Environ Med 2009; 80(3):211.

37. White VL, Chaturvedi AK, Canfield DV, Garber M. Association of postmortem blood hemoglobin A_{1c} levels with diabetic conditions in aviation accidents pilot fatalities. Washington, DC: U.S. Department of Transportation, Federal Aviation Administration, Office of Aerospace Medicine; 2001 Jul. Report No. DOT/FAA/AM-01/12.

38. WIN. Prescription medications for the treatment of obesity. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Weight-Control Information Network (WIN); 2004 Nov. Report No. 07-4191.html.